Exercise with Some Limits is Believed to be Beneficial for Glaucoma Patients In most cases exercise is good for glaucoma patients if performed properly. Although there are a few exceptions, some research supports the benefits of moderate exercise for glaucoma patients. The exercise should be moderate and not extreme since there is now research showing extreme exercise creates large amounts of free radicals within the body, which can have its own set of problems.
The iStent is a Promising New Treatment for Glaucoma Patients that also Need Cataract Surgery It is a promising era for glaucoma patients. On June 25, 2012, the Food & Drug Administration (FDA) approved the iStent Trabecular Micro-Bypass Stent System, Model GTS100R/L. The iStent is the first device ever approved to be used in conjunction with cataract surgery for adults with moderate open angle glaucoma.
FDA Approves a New, Effective Glaucoma Medicine The first preservative free prostaglandin ophthalmic solution eye drop medicine used to treat glaucoma has been approved by the U.S. Food and Drug Administration. The new preservative free glaucoma medicine is known as ZIOPTAN™ (tafluprost ophthalmic solution 0.0015%). ZIOPTAN (pronounced zye-OP-tan), distributed by Merck (NYSE: MRK) is approved for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma, the most common type of glaucoma. ZIOPTAN is one of several prescription eye drops in a category called prostaglandin analogs. Other medicines in this glaucoma treatment category include Travatan Z, Lumigan and Xalatan. A prostaglandin analog is typically the first type of medicine prescribed by an eye doctor in the treatment of open angle glaucoma. The significance of Zioptan is that it is the first and only preservative free prostaglandin analog. It is often believed that preservatives in the eye drops can possibly cause side effects that cause problems with the outer ocular surface such as the cornea and conjunctiva. ZIOPTAN and other Prostaglandin Glaucoma Medicines are Considered the Most Potent Eye Drops for Lowering Intraocular Pressure
Thin Corneas are a Major Risk Factor for Glaucoma A major national study called the Ocular Hypertension and Treatment Study (OHTS) proved that the thickness of the cornea is one of the most powerful predictors for the development of glaucoma. Eyes with a corneal thickness of 555 microns or less (thinner corneas) had a 300% greater risk of developing glaucoma than those eyes with a corneal thickness of 588 microns or more.
DISCLAIMER: The information on this website is for educational purposes only. The information on this website is not meant to diagnose or treat any disease(s). Only a licensed doctor can diagnose or treat disease. No information on this website has been evaluated by the U.S. Food and Drug Administration.